Abemaciclib mesylate (LY2835219)

For research use only. Not for use in humans.

目录号:S7158 中文名称:甲磺酸阿贝西尼

Abemaciclib mesylate (LY2835219) Chemical Structure

CAS No. 1231930-82-7

Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 4644.52 现货
RMB 2203.44 现货
RMB 3333.88 现货
RMB 6544.35 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Abemaciclib mesylate (LY2835219)发表文献53篇:

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。
靶点
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
2 nM 10 nM
体外研究

LY2835219是一种口服有效的细胞周期蛋白依赖性激酶(CDK)抑制剂,靶向作用于CDK4(cyclin D1)和CDK6(cyclin D3)细胞周期通路,具有潜在的抗肿瘤活性。LY2835219特异性抑制CDK4和6,从而在早G1期抑制视网膜母细胞瘤(Rb)蛋白磷酸化。抑制Rb磷酸化,防止CDK-介导的G1-S期转换,从而使细胞周期停滞在G1期,抑制DNA合成,且抑制癌细胞生长。某些类型的癌症中丝/苏氨酸激酶CDK4/6的过表达,导致细胞周期调节失控。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human COLO205 cells MknpSpVv[3Srb36gZZN{[Xl? NXHnSYU3OjRiaB?= Mk\hTY5pcWKrdHnvckBw\iCFRFu0M|YhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{Bu[XirbYXtJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdzIIDoZZNmKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>? M2DO[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG1OVcyLz5{NkGxOVU4OTxxYU6=
human COLO205 cells MVfGeY5kfGmxbjDhd5NigQ>? NHPhOpozPCCq MmO0TY5pcWKrdHnvckBw\iCFRFu0M|YhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGLiJJBpd3OyaH;yfYxifGmxbjDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBt[XOncj3zZ4FvdmmwZzDmcJVwemW|Y3XuZ4UhdWmlcn;wcIF1\SCleYTvcYV1emmlIHHuZYx6e2m| NEnUOYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
insect cells  NGX1fZlHfW6ldHnvckBie3OjeR?= MYC1NEBucW6| M4DWeWlvcGmkaYTpc44hd2ZiaIXtZY4hS0SNND;jfYNtcW5iREGg[ZhxemW|c3XkJIlvKGmwc3XjeEBk\WyuczDhd5Nme3OnZDDhd{BxcG:|cHjvdplt[XSrb36gc4YhS1SURjDh[pRmeiB3MDDtbY5{KGK7IH3pZ5JweGyjdHWgd4NqdnSrbHzheIlwdiClb4XueIVzNCCLQ{WwQVIhdk1? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
insect cells  MnHtSpVv[3Srb36gZZN{[Xl? MW[1NEBucW6| NVH2XVFPS2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBpfW2jbjDDSGs1N2O7Y3zpckBFOSCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KGG|c3Xzd4VlKGG|IIDoc5NxcG:{eXzheIlwdiCxZjDDWHJHKGGodHXyJFUxKG2rboOgZpkhVWmlaHHlcIl{NU2nboTlckBxdG:2IHHuZYx6e2m|IHnuJJBz\XOnbnPlJI9nKEGWUDygT4k:OC54IH7N MlX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUW1O|EoRjJ4MUG1OVcyRC:jPh?=
HCT116 NV7wO5NkSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MX63NkBpenN? M4\zZWlEPTBiPTCwMlU1KM7:TR?= Mnq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkWzOFEoRjNyMU[1N|QyRC:jPh?=
MCF7 NHezT49CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M2eyclczKGi{cx?= MX7JR|UxKD1iMD63NUDPxE1? MmHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkWzOFEoRjNyMU[1N|QyRC:jPh?=
PANC1 Ml2zRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MXm3NkBpenN? MXHJR|UxKD1iNT65OEDPxE1? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4NUO0NUc,OzBzNkWzOFE9N2F-
Sf9 NVvFVndXTnWwY4Tpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKEOGS{GvR5lkdGmwIFKgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4h[mGldXzveolz[WxiaX7m[YN1\WRiaX7z[YN1KFOoOTDj[YxteyC3c3nu[{BpcXO2b37lJGgyKGG|IIP1ZpN1emG2ZTDpckBxemW|ZX7j[UBw\iCdZ3HtcYEuOzOSXVHUVEwhUUN3MDC9JFAvOzdzIN88UU4> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd2MUi1N{c,OjZ5NEG4OVM9N2F-
Sf9 NHXqfohHfW6ldHnvckBie3OjeR?= NHmwOG46OCCvaX7z M{D1WGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzRiKESgeI8hOzB|IILld4llfWW|KT;jfYNtcW5iREGgLFQhfG9iMkm1JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy|IIXzbY5oKENvdHXycYlv[WxicnX0bY5w[myjc4TvcYEh\nKjZ33lcpQh[XNic4Xid5Rz[XSnIHHmeIVzKDlyIH3pcpMh[nliW3fhcY1iNTN|UG3BWHAh[mG|ZXSgcYlkem:kZYThJJNkcW62aXzsZZRqd25iY3;1cpRqdixiS3mgQUAxNjByMjFOwG0v MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf9 NF7mbpZHfW6ldHnvckBie3OjeR?= M2jq[VkxKG2rboO= NIC5NHJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIZ2dGxibHXu[5RpKGi3bXHuJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCFRFu2JEgyKHSxIEOyOkBz\XOrZIXld{kw[3mlbHnuJGQyKCh2IITvJFI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDDMZRmem2rbnHsJJJmfGmwb3LsZZN1d22jIH\yZYdu\W62IHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHto[W2vYT2zN3BeSVSSIHLhd4VlKG2rY4LvZoV1[SC|Y3nueIltdGFuIFvpJF0hOC5yMTFOwG0v M3nEUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
Sf21 MkjYSpVv[3Srb36gZZN{[Xl? NFG3e2tKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGMufGW{bXnuZYwhUGm|Nj30ZYdo\WRiQ1TLO{9kgWOuaX6gTE9PNXSncn3pcoFtKEeVVD30ZYdo\WRiTVHUNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiY3TrO{B{fWK|dILheIUheGWydHnk[UwhU2liPTCzMlkyKM7:TT6= M1fpdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
COLO205 M{fPS2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXS5OkBpenN? NIDzSVZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGNEUy16IHHzd4F6NCCLQ{WwJF0hOC52NjFOwG0v NXS4RWdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwO|QzPTRpPkK5NFc1OjV2PD;hQi=>
U87MG NYPUfIF2SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MXm3NkBpenN? M3u1RWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFTBVGkhe3SjaX7pcoch[mG|ZXSgZZN{[XluIFnDOVAhRSByLkC0PFEh|ryPLh?= NV64dZZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyOFc5PTdpPkK5NlQ4QDV5PD;hQi=>
Sf9 MWDGeY5kfGmxbjDhd5NigQ>? NILkWo1KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt2IDjTOEB1dyCHM{CzJJJme2mmdXXzLU9EgWOuaX6gSFEhMFF2IITvJGkzQTVicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMhfXOrbnegVoIheHKxdHXpckApPzd|IITvJFkzQCC{ZYPp[JVmeyliYYOgd5Vje3S{YYTlJIlvKHC{ZYPlcoNmKG:oIGuzN3BeNUGWUDDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pIH3leIhw\CxiSVO1NEA:KDBwMECyJO69VS5? MlzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 MUPGeY5kfGmxbjDhd5NigQ>? MoW1PVAhdWmwcx?= M{PLO2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR2RMPiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDobZN1d26nIFixJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JGFFWC2JbH:gZZN{[XluIFnDOVAhRSByLkCwO|gh|ryPLh?= NWDZS2lIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Nlk5OzJpPkK5OFI6QDN{PD;hQi=>
Sf9 NH3BNFRHfW6ldHnvckBie3OjeR?= NVfRe2lJUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNNDCoUVEhfG9iQUOyOkBz\XOrZIXld{kwS3mlbHnuJGQyKCiTNDD0c{BKOjl3IILld4llfWW|KTDlfJBz\XO|ZXSgbY4he2Z7IHPlcIx{KHW|aX7nJHJjKHC{b4TlbY4hMDd5MzD0c{A6OjhicnXzbYR2\XNrIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDbN|NRZS2DVGCgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFnDOVAhRSByLkCxJO69VS5? M3Hhc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEK5PFMzLz5{OUSyPVg{OjxxYU6=
Sf9 NHvqXIdHfW6ldHnvckBie3OjeR?= NVHrUZFlQTBibXnudy=> MX\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFPET|EwS3mlbHnuJGQ{KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIHjpd5RwdmViSEGgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgRWRRNUeubzDhd5NigSxiSVO1NEA:KDBwMEW2JO69VS5? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
MDA-MB-231 MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFv MoLvO|IhcHK| NILy[|dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiYYPzZZktKEmFNUCgQUAxNjF7MTFOwG0v Mm\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
COLO205 NIjqeIdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGw NYHMRYFkQTZiaILz M{noU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU|IxPSClZXzsd{Bi\nSncjC5OkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOjF5IN88UU4> NH;C[ZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1PVI4PCd-Mkm0OVkzPzR:L3G+
MDA-MB-468 M1uzdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5? NUjuSmV6QTZiaILz MlrrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuPDZ6IHPlcIx{KGGodHXyJFk3KGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPC56MEig{txONg>? MlviQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=
COLO205 M1O1WWlvcGmkaYTpc44hd2ZiQ1TLOEBqdiCqdX3hci=> NH3QcmoxNjFidH:gNVAhfU1? MYmyOEBpenN? NUTSPGJnUW6qaXLpeIlwdiCxZjDDSGs1KGmwIHj1cYFvKEORTF:yNFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIITveIFtKFKkIIDyc5RmcW5ibHX2[Ywh[XRiMD6xJJRwKDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q> MnLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=
COLO205 MlzaR4VtdCCleXPs[UBie3OjeR?= NEjhSGl2eCC2bzCxNEB2VQ>? M4fJfVI1KGi{cx?= NI\HTWhE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBEV0yRMkC1JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJJVxKHSxIEGwJJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM> MoHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Rb(S780) / Rb / p21; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated concentrations (A)

p-ERK / ERK / p-Akt / Akt / p-mTOR(S2448) / mTOR; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated time points (B).

pRb(S795) / E2F1 / Cyclin A2 / Cyclin E2; 

PubMed: 27748766     


(c) MCF-7 and MR cells were treated with 100 nm LY2835219 and collected at indicated times. Immunoblots were performed with the indicated antibodies. (d) MCF-7 and MR cells were treated with increasing concentrations of LY2835219 and harvested after 24 h; lysates were then subjected to immunoblotting.

26909611 27748766
Growth inhibition assay
Cell viability; 

PubMed: 26909611     


Cell viability of OSC-19, FaDu, and YD-10B cells treated with LY2835219 at indicated concentrations. Data are representative of three independent experiments: mean ± SEM.

26909611
体内研究 LY2835219-MsOH处理脑的剂量百分比为0.5–3.9%。LY2835219-MsOH处理皮下和颅内胶质瘤模型(U87MG),抑制肿瘤生长,这种作用存在剂量依赖性,不管是单独处理,还是与Temozolomide联用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 Water 100 mg/mL (165.92 mM)
DMSO 83 mg/mL (137.71 mM)
Ethanol '''24 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
100mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 602.7
化学式

C27H32F2N8.CH4O3S

CAS号 1231930-82-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04967521 Not yet recruiting Drug: Abemaciclib|Drug: Placebo Advanced Dedifferentiated Liposarcoma Sarcoma Alliance for Research through Collaboration|Eli Lilly and Company September 2021 Phase 3
NCT04750928 Not yet recruiting Drug: Abemaciclib Neurofibromatosis 1 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 7 2021 Phase 1|Phase 2
NCT04941274 Recruiting Drug: Abemaciclib Kaposi Sarcoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 7 2021 Phase 1|Phase 2
NCT04169074 Recruiting Drug: Abemaciclib|Drug: Abemaciclib plus nivolumab HNSCC University of Arizona June 16 2021 Phase 2
NCT04921904 Not yet recruiting Drug: Abemaciclib|Drug: Ramucirumab Metastatic Esophageal Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma Baylor Research Institute June 2021 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is your product S7158 LY2835219 “mesylate salt form”?

  • 回答:

    Our S7158 LY2835219 is mesylate salt form.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)供应商 | 采购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)价格 | Abemaciclib mesylate (LY2835219)生产 | 订购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID